Rezolute Inc (RZLT)

$4.91 -0.04 (-0.81%)
Market Cap 472.79M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,794,800
Avg Vol 1,953,398
Day's Range N/A - N/A
Shares Out 96.29M
Stochastic %K 12%
Beta 0.54
Analysts Strong Sell
Price Target $7.67

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
KONGLIVES1
KONGLIVES1 Jul. 1 at 9:09 PM
$RZLT this sock is starting to make me (grow old) I keep waiting for it to break out and it retraces 
0 · Reply
Monty3030
Monty3030 Jun. 30 at 9:22 PM
$RZLT 9.25 days to cover 20.75% short interest
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:51 PM
$CALC Part 1 - To follow is an email I sent to $CALC investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:50 PM
$CALC Part 2 - Email: I cannot think of a more motivated group of people than the current $CALC management. You own 52% of the shares. Before the dip the value was $37 mil and current value is $4 mil. I estimate you collectively have a cost bases of about $18 mil. If you could only learn from Rezolute Inc., $RZLT, management. Their share price dropped from $10 to $1 in December in less than one day. Management stepped in and purchased the stock at a deep discount like I am doing. In a little over a month and a half the Rezolute price per share peaked at $4 and is holding above $3.5 a share.
0 · Reply
Dan_o
Dan_o Jun. 27 at 8:49 PM
rt 1 -low is an email I sent to investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Monty3030
Monty3030 Jun. 26 at 8:37 PM
$RZLT Where is all this volume coming from? Over 6 million now!! Someone big is buying...
1 · Reply
Monty3030
Monty3030 Jun. 26 at 8:10 PM
$RZLT Crazy volume today. Over 5 million!!
0 · Reply
Biotechnicity
Biotechnicity Jun. 26 at 6:43 PM
$RFL So, many of the 96%ers (those retail retail investors who underperform market indexes ALL THE TIME) and block the 4%ers who criticize their assumptions) will tell you that I’m wrong about not needing a TRANSPORT-NPC stat-sig trial result. Here is a post on the $RZLT board regarding FDA guidance in rare disease settings (NPC is still considered an Ultra Rare Disease). https://stocktwits.com/oaksapollo/message/657366402 Recognize too that FDA approved arimoclomol (MYPLYFFA) based on… ▪️A Phase-2 trial of 36 patients that was expanded to 50 patients to win approval. ▪️A trial result that was not stat-sig but made stat-sig by FDA researchers who found two, protein null patients in the active arm that were not responsive to therapy and removed them which, in turn, made their trial stat-sig. ▪️A trial that included MISSING DATA from both arms 4 active in the active and 1 in control. Every CEO that ushered this drug to approval promised to find that missing data but did not. A travesty!
0 · Reply
KONGLIVES1
KONGLIVES1 Jun. 25 at 8:00 PM
$RZLT consolidation seems to be going on around five dollars before it’s moves up 🫡 
0 · Reply
AnomalyDetective
AnomalyDetective Jun. 25 at 12:48 PM
💥 $MU (Premium portfolio / Large Cap portfolio) beats big, up over +17% premarket with all new Week 27 MDA picks out for members today after the close. 💥 $SLDB (Week 26 MDA) first pick of the week to break 10% for members up over 28% through Thursday. 💠Extending the count to 372 weeks with at least one pick gaining over 10% in less than a week. 💠 All new Long Term portfolios midyear update to be released this weekend for members. $RZLT (CFO Insider Trading) up +112.7% YTD. https://seekingalpha.com/mp/1201-value-momentum-breakouts Credit: vmbreakouts.com @vmbreakouts
0 · Reply
Latest News on RZLT
Rezolute Slides: Corporate presentation

Jun 26, 2026, 7:00 AM EDT - 8 days ago

Rezolute Slides: Corporate presentation

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Jun 17, 2026, 7:00 AM EDT - 17 days ago

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute price target raised to $11, named a Best Idea at Guggenheim

2026-06-15T10:41:18.000Z - 19 days ago

Rezolute price target raised to $11, named a Best Idea at Guggenheim

Rezolute Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 4 weeks ago

Rezolute Transcript: Jefferies Global Healthcare Conference 2026

Rezolute Slides: FY 2026

Jun 4, 2026, 3:45 PM EDT - 4 weeks ago

Rezolute Slides: FY 2026

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Jun 4, 2026, 7:30 AM EDT - 4 weeks ago

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute price target raised to $14 from $10 at Maxim

2026-06-03T15:04:08.000Z - 4 weeks ago

Rezolute price target raised to $14 from $10 at Maxim

Rezolute price target raised to $6 from $5 at Wedbush

2026-06-03T12:16:54.000Z - 4 weeks ago

Rezolute price target raised to $6 from $5 at Wedbush

Rezolute upgraded to Outperform from Market Perform at Citizens

2026-06-03T08:36:37.000Z - 4 weeks ago

Rezolute upgraded to Outperform from Market Perform at Citizens

Rezolute price target raised to $6 from $5 at BTIG

2026-06-02T19:55:11.000Z - 4 weeks ago

Rezolute price target raised to $6 from $5 at BTIG

Rezolute price target raised to $14 from $10 at Maxim

2026-06-02T19:00:14.000Z - 4 weeks ago

Rezolute price target raised to $14 from $10 at Maxim

Rezolute provides interim update on ersodetug study

2026-06-02T11:31:37.000Z - 4 weeks ago

Rezolute provides interim update on ersodetug study

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Jun 2, 2026, 7:00 AM EDT - 4 weeks ago

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute price target raised to $10 from $4 at Maxim

2026-05-14T14:28:58.000Z - 7 weeks ago

Rezolute price target raised to $10 from $4 at Maxim

Rezolute reports Q3 EPS (16c), consensus (17c)

2026-05-12T21:34:01.000Z - 7 weeks ago

Rezolute reports Q3 EPS (16c), consensus (17c)

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026, 4:05 PM EDT - 7 weeks ago

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 7 weeks ago

Rezolute Earnings release: Q3 2026

Rezolute Quarterly report: Q3 2026

May 12, 2026, 4:00 PM EDT - 7 weeks ago

Rezolute Quarterly report: Q3 2026

Rezolute to Participate in Upcoming Investor Conferences

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 2 months ago

Rezolute Slides: Corporate presentation

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

2026-05-01T16:21:30.000Z - 2 months ago

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

May 1, 2026, 12:15 PM EDT - 2 months ago

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Rezolute, Inc. Investigated by the Portnoy Law Firm

Apr 24, 2026, 9:00 AM EDT - 2 months ago

Rezolute, Inc. Investigated by the Portnoy Law Firm

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Apr 21, 2026, 7:00 AM EDT - 2 months ago

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Rezolute Slides: Corporate presentation

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Rezolute Slides: Corporate presentation

Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI

2026-03-25T10:46:08.000Z - 3 months ago

Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI

Rezolute upgraded to Outperform from Neutral at Wedbush

2026-03-25T10:37:36.000Z - 3 months ago

Rezolute upgraded to Outperform from Neutral at Wedbush

Rezolute provides update on sunRIZE study following Type B meeting with FDA

2026-03-24T11:26:35.000Z - 3 months ago

Rezolute provides update on sunRIZE study following Type B meeting with FDA

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Mar 24, 2026, 7:00 AM EDT - 3 months ago

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Rezolute to Participate in the Citizens Life Sciences Conference

Mar 4, 2026, 7:00 AM EST - 4 months ago

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute management to meet with Maxim

2026-03-03T14:56:44.000Z - 4 months ago

Rezolute management to meet with Maxim

Rezolute reports Q2 EPS (22c), consensus (18c)

2026-02-12T21:16:42.000Z - 5 months ago

Rezolute reports Q2 EPS (22c), consensus (18c)

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 12, 2026, 4:05 PM EST - 5 months ago

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Quarterly report: Q2 2026

Feb 12, 2026, 4:00 PM EST - 5 months ago

Rezolute Quarterly report: Q2 2026

Rezolute Earnings release: Q2 2026

Feb 12, 2026, 4:00 PM EST - 5 months ago

Rezolute Earnings release: Q2 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 5 months ago

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute price target raised to $2 from $1 at Wedbush

2026-01-08T13:05:22.000Z - 6 months ago

Rezolute price target raised to $2 from $1 at Wedbush

Rezolute shares findings from Expanded Access Program in tumor HI

2026-01-07T12:17:20.000Z - 6 months ago

Rezolute shares findings from Expanded Access Program in tumor HI

Rezolute shares observations from Phase 3 sunRIZE study in congenital HI

2026-01-07T12:10:43.000Z - 6 months ago

Rezolute shares observations from Phase 3 sunRIZE study in congenital HI

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Jan 7, 2026, 7:00 AM EST - 6 months ago

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Rezolute Slides: Corporate Presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Rezolute Slides: Corporate Presentation

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 2:39 PM EST - 7 months ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Rezolute Transcript: Study Result

Dec 11, 2025, 8:30 AM EST - 7 months ago

Rezolute Transcript: Study Result

Rezolute Press release: Study Result

Dec 11, 2025, 8:30 AM EST - 7 months ago

Rezolute Press release: Study Result

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:05 AM EST - 7 months ago

Rezolute's rare disease drug fails main goal in late-stage trial

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Dec 11, 2025, 7:00 AM EST - 7 months ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Transcript: AGM 2025

Nov 19, 2025, 6:00 PM EST - 8 months ago

Rezolute Transcript: AGM 2025

Rezolute Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 8 months ago

Rezolute Slides: Corporate Presentation

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 8 months ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Transcript: Status Update

Nov 10, 2025, 12:00 PM EST - 8 months ago

Rezolute Transcript: Status Update

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 8 months ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Quarterly report: Q1 2026

Nov 6, 2025, 4:00 PM EST - 8 months ago

Rezolute Quarterly report: Q1 2026

Rezolute Earnings release: Q1 2026

Nov 6, 2025, 4:00 PM EST - 8 months ago

Rezolute Earnings release: Q1 2026

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 8 months ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute Proxy statement: Proxy Filing

Oct 7, 2025, 8:00 AM EDT - 9 months ago

Rezolute Proxy statement: Proxy Filing

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 17, 2025, 4:05 PM EDT - 10 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute Annual report: Q4 2025

Sep 17, 2025, 4:00 PM EDT - 10 months ago

Rezolute Annual report: Q4 2025

Rezolute Earnings release: Q4 2025

Sep 17, 2025, 4:00 PM EDT - 10 months ago

Rezolute Earnings release: Q4 2025

Rezolute Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 12:20 PM EDT - 10 months ago

Rezolute Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

KONGLIVES1
KONGLIVES1 Jul. 1 at 9:09 PM
$RZLT this sock is starting to make me (grow old) I keep waiting for it to break out and it retraces 
0 · Reply
Monty3030
Monty3030 Jun. 30 at 9:22 PM
$RZLT 9.25 days to cover 20.75% short interest
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:51 PM
$CALC Part 1 - To follow is an email I sent to $CALC investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:50 PM
$CALC Part 2 - Email: I cannot think of a more motivated group of people than the current $CALC management. You own 52% of the shares. Before the dip the value was $37 mil and current value is $4 mil. I estimate you collectively have a cost bases of about $18 mil. If you could only learn from Rezolute Inc., $RZLT, management. Their share price dropped from $10 to $1 in December in less than one day. Management stepped in and purchased the stock at a deep discount like I am doing. In a little over a month and a half the Rezolute price per share peaked at $4 and is holding above $3.5 a share.
0 · Reply
Dan_o
Dan_o Jun. 27 at 8:49 PM
rt 1 -low is an email I sent to investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Monty3030
Monty3030 Jun. 26 at 8:37 PM
$RZLT Where is all this volume coming from? Over 6 million now!! Someone big is buying...
1 · Reply
Monty3030
Monty3030 Jun. 26 at 8:10 PM
$RZLT Crazy volume today. Over 5 million!!
0 · Reply
Biotechnicity
Biotechnicity Jun. 26 at 6:43 PM
$RFL So, many of the 96%ers (those retail retail investors who underperform market indexes ALL THE TIME) and block the 4%ers who criticize their assumptions) will tell you that I’m wrong about not needing a TRANSPORT-NPC stat-sig trial result. Here is a post on the $RZLT board regarding FDA guidance in rare disease settings (NPC is still considered an Ultra Rare Disease). https://stocktwits.com/oaksapollo/message/657366402 Recognize too that FDA approved arimoclomol (MYPLYFFA) based on… ▪️A Phase-2 trial of 36 patients that was expanded to 50 patients to win approval. ▪️A trial result that was not stat-sig but made stat-sig by FDA researchers who found two, protein null patients in the active arm that were not responsive to therapy and removed them which, in turn, made their trial stat-sig. ▪️A trial that included MISSING DATA from both arms 4 active in the active and 1 in control. Every CEO that ushered this drug to approval promised to find that missing data but did not. A travesty!
0 · Reply
KONGLIVES1
KONGLIVES1 Jun. 25 at 8:00 PM
$RZLT consolidation seems to be going on around five dollars before it’s moves up 🫡 
0 · Reply
AnomalyDetective
AnomalyDetective Jun. 25 at 12:48 PM
💥 $MU (Premium portfolio / Large Cap portfolio) beats big, up over +17% premarket with all new Week 27 MDA picks out for members today after the close. 💥 $SLDB (Week 26 MDA) first pick of the week to break 10% for members up over 28% through Thursday. 💠Extending the count to 372 weeks with at least one pick gaining over 10% in less than a week. 💠 All new Long Term portfolios midyear update to be released this weekend for members. $RZLT (CFO Insider Trading) up +112.7% YTD. https://seekingalpha.com/mp/1201-value-momentum-breakouts Credit: vmbreakouts.com @vmbreakouts
0 · Reply
oaksapollo
oaksapollo Jun. 24 at 7:32 PM
$RZLT FDA just published a draft guidance called "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products." In it they state that "The clinical context is critical to informing the approach to establishing substantial evidence of effectiveness. Considerations include, for example, disease severity, unmet need, and disease rarity." "These clinical considerations should not be considered individually, but rather holistically, as more than one consideration will often be relevant." These statements are from a section entitled "Clinical Circumstances Where Flexibility May Be Warranted." Rezolute has all 3 considerations going in their favor: severity, unmet need, and rarity. No question in my mind now that ersodetug will be approved.
0 · Reply
AnomalyDetective
AnomalyDetective Jun. 24 at 4:00 PM
$RZLT CFO insider trading stock part of the January portfolio +18.1% YTD for members still going strong on separate MDA breakout signals. $RZLT up +121.4% YTD and $SVCO highlighted previously up +190.2% YTD despite large declines today. 💥 All new midyear long term portfolios out for members only ahead of the July midyear start here: https://seekingalpha.com/mp/1201-value-momentum-breakouts 💥 This will include new portfolios for: 💠Piotroski-Graham value +17.4% / +19.0% YTD adjusted for dividends. 💠 Positive Forensic -5.2% / -0.8% YTD adjusted for dividends. 💠 Negative Forensic +15.2% / +15.7% YTD adjusted for dividends. 💠 Growth & Dividend +6.9% / +9.75% YTD adjusted for dividends. 💠 CFO Insider Trading +18.1% YTD 💠 Large Cap bonus MDA selections +118.4% YTD and new selections for mid-year and weekly. Credit http://vmbreakouts.com @vmbreakouts
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 23 at 8:15 PM
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth https://ow.ly/QutO50Zg1f6 Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities. $RZLT
0 · Reply
oaksapollo
oaksapollo Jun. 23 at 7:00 PM
$RZLT Hmm...I had some covered calls exercised last week which resulting in me selling some shares at $5. Buy back here or wait? (current price $4.93)
0 · Reply
KONGLIVES1
KONGLIVES1 Jun. 23 at 6:47 PM
$RZLT Tech sell off causing selling off
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 22 at 6:44 PM
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data https://ow.ly/QWyi50ZfoBl Rezolute Inc. ( $RZLT ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026.
0 · Reply
Marketman707
Marketman707 Jun. 22 at 11:35 AM
$RZLT SQUEEEZZEEEE!!
0 · Reply
KONGLIVES1
KONGLIVES1 Jun. 19 at 12:19 AM
$RZLT volume has been growing great sign 💴
0 · Reply
Monty3030
Monty3030 Jun. 18 at 8:01 PM
$RZLT $5.02 close!!! Let's gooooooo!!
0 · Reply
Monty3030
Monty3030 Jun. 18 at 7:50 PM
$RZLT Come on stay above $5, ten minutes left!!
0 · Reply
Monty3030
Monty3030 Jun. 18 at 3:34 PM
$RZLT Let's close over $5 today to pop up or more people's stock screeners!!
0 · Reply
KONGLIVES1
KONGLIVES1 Jun. 18 at 2:23 PM
$RZLT go baby go
0 · Reply